Distinct inactive conformations of the dopamine D2 and D3 receptors correspond to different extents of inverse agonism

  1. J Robert Lane  Is a corresponding author
  2. Ara M Abramyan
  3. Pramisha Adhikari
  4. Alastair C Keen
  5. Kuo-Hao Lee
  6. Julie Sanchez
  7. Ravi Kumar Verma
  8. Herman D Lim
  9. Hideaki Yano
  10. Jonathan A Javitch  Is a corresponding author
  11. Lei Shi  Is a corresponding author
  1. University of Nottingham, United Kingdom
  2. National Institute on Drug Abuse, National Institutes of Health, United States
  3. Monash University, Australia
  4. Columbia University, United States

Abstract

By analyzing and simulating inactive conformations of the highly-homologous dopamine D2 and D3 receptors (D2R and D3R), we find that eticlopride binds D2R in a pose very similar to that in the D3R/eticlopride structure but incompatible with the D2R/risperidone structure. In addition, risperidone occupies a sub-pocket near the Na+ binding site, whereas eticlopride does not. Based on these findings and our experimental results, we propose that the divergent receptor conformations stabilized by Na+-sensitive eticlopride and Na+-insensitive risperidone correspond to different degrees of inverse agonism. Moreover, our simulations reveal that the extracellular loops are highly dynamic, with spontaneous transitions of extracellular loop 2 from the helical conformation in the D2R/risperidone structure to an extended conformation similar to that in the D3R/eticlopride structure. Our results reveal previously unappreciated diversity and dynamics in the inactive conformations of D2R. These findings are critical for rational drug discovery, as limiting a virtual screen to a single conformation will miss relevant ligands.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files.

Article and author information

Author details

  1. J Robert Lane

    Division of Pharmacology, Physiology and Neuroscience, School of Life Sciences, University of Nottingham, Nottingham, United Kingdom
    For correspondence
    Rob.Lane@nottingham.ac.uk
    Competing interests
    The authors declare that no competing interests exist.
  2. Ara M Abramyan

    Computational Chemistry and Molecular Biophysics Unit, National Institute on Drug Abuse, National Institutes of Health, Baltimore, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Pramisha Adhikari

    Computational Chemistry and Molecular Biophysics Unit, National Institute on Drug Abuse, National Institutes of Health, Baltimore, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Alastair C Keen

    Division of Pharmacology, Physiology and Neuroscience, School of Life Sciences, University of Nottingham, Nottingham, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  5. Kuo-Hao Lee

    Computational Chemistry and Molecular Biophysics Unit, National Institute on Drug Abuse, National Institutes of Health, Baltimore, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Julie Sanchez

    Division of Pharmacology, Physiology and Neuroscience, School of Life Sciences, University of Nottingham, Nottingham, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  7. Ravi Kumar Verma

    Computational Chemistry and Molecular Biophysics Unit, National Institute on Drug Abuse, National Institutes of Health, Baltimore, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Herman D Lim

    Department of Pharmacology and Medicinal Chemistry, Monash University, Parkville, Australia
    Competing interests
    The authors declare that no competing interests exist.
  9. Hideaki Yano

    Computational Chemistry and Molecular Biophysics Unit, National Institute on Drug Abuse, National Institutes of Health, Baltimore, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Jonathan A Javitch

    Department of Psychiatry, Columbia University, New York, United States
    For correspondence
    jaj2@cumc.columbia.edu
    Competing interests
    The authors declare that no competing interests exist.
  11. Lei Shi

    Computational Chemistry and Molecular Biophysics Unit, National Institute on Drug Abuse, National Institutes of Health, Baltimore, United States
    For correspondence
    lei.shi2@nih.gov
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4137-096X

Funding

National Institutes of Health (Z1A DA000606-03)

  • Lei Shi

National Institutes of Health (MH54137)

  • Jonathan A Javitch

National Health and Medical Research Council (APP1049564)

  • J Robert Lane

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Metrics

  • 2,215
    views
  • 357
    downloads
  • 29
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. J Robert Lane
  2. Ara M Abramyan
  3. Pramisha Adhikari
  4. Alastair C Keen
  5. Kuo-Hao Lee
  6. Julie Sanchez
  7. Ravi Kumar Verma
  8. Herman D Lim
  9. Hideaki Yano
  10. Jonathan A Javitch
  11. Lei Shi
(2020)
Distinct inactive conformations of the dopamine D2 and D3 receptors correspond to different extents of inverse agonism
eLife 9:e52189.
https://doi.org/10.7554/eLife.52189

Share this article

https://doi.org/10.7554/eLife.52189

Further reading

    1. Biochemistry and Chemical Biology
    2. Microbiology and Infectious Disease
    Eva Herdering, Tristan Reif-Trauttmansdorff ... Ruth Anne Schmitz
    Research Article

    Glutamine synthetases (GS) are central enzymes essential for the nitrogen metabolism across all domains of life. Consequently, they have been extensively studied for more than half a century. Based on the ATP-dependent ammonium assimilation generating glutamine, GS expression and activity are strictly regulated in all organisms. In the methanogenic archaeon Methanosarcina mazei, it has been shown that the metabolite 2-oxoglutarate (2-OG) directly induces the GS activity. Besides, modulation of the activity by interaction with small proteins (GlnK1 and sP26) has been reported. Here, we show that the strong activation of M. mazei GS (GlnA1) by 2-OG is based on the 2-OG dependent dodecamer assembly of GlnA1 by using mass photometry (MP) and single particle cryo-electron microscopy (cryo-EM) analysis of purified strep-tagged GlnA1. The dodecamer assembly from dimers occurred without any detectable intermediate oligomeric state and was not affected in the presence of GlnK1. The 2.39 Å cryo-EM structure of the dodecameric complex in the presence of 12.5 mM 2-OG demonstrated that 2-OG is binding between two monomers. Thereby, 2-OG appears to induce the dodecameric assembly in a cooperative way. Furthermore, the active site is primed by an allosteric interaction cascade caused by 2-OG-binding towards an adaption of an open active state conformation. In the presence of additional glutamine, strong feedback inhibition of GS activity was observed. Since glutamine dependent disassembly of the dodecamer was excluded by MP, feedback inhibition most likely relies on the binding of glutamine to the catalytic site. Based on our findings, we propose that under nitrogen limitation the induction of M. mazei GS into a catalytically active dodecamer is not affected by GlnK1 and crucially depends on the presence of 2-OG.

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics
    Joar Esteban Pinto Torres, Mathieu Claes ... Yann G-J Sterckx
    Research Article

    African trypanosomes are the causative agents of neglected tropical diseases affecting both humans and livestock. Disease control is highly challenging due to an increasing number of drug treatment failures. African trypanosomes are extracellular, blood-borne parasites that mainly rely on glycolysis for their energy metabolism within the mammalian host. Trypanosomal glycolytic enzymes are therefore of interest for the development of trypanocidal drugs. Here, we report the serendipitous discovery of a camelid single-domain antibody (sdAb aka Nanobody) that selectively inhibits the enzymatic activity of trypanosomatid (but not host) pyruvate kinases through an allosteric mechanism. By combining enzyme kinetics, biophysics, structural biology, and transgenic parasite survival assays, we provide a proof-of-principle that the sdAb-mediated enzyme inhibition negatively impacts parasite fitness and growth.